BigClassActions.com
Advertisement

Johnson & Johnson to Pay $81M In Topamax Settlement

- by

Washington, DC: Johnson & Johnson has agreed to pay $81 million to the US Justice Department as settlement over allegations that the pharmaceutical company illegally promoted the epilepsy drug Topamax for unapproved uses, specifically for psychiatric indications.

Topamax is approved by the FDA for use in epilepsy patients and migraine prevention

According to a report in the New York Times, Ortho-McNeil-Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson, will pay more than $75 million, and Ortho-McNeil Pharmaceutical will plead guilty to one misdemeanor violation of the Food, Drug and Cosmetic Act and pay a $6.1 million criminal fine.

According to the Justice Department, Ortho-McNeil Pharmaceutical used a program called Doctor-for-a-Day to promote sales of Topamax for psychiatric indications. Sales for the drug reached $2 billion annually by 2006, and peaked in 2008 at $2.7 billion. A generic version of the drug came online in 2009, and subsequently Johnson & Johnson's sales plunged that year to $148 million.

Legal Help

If you have a similar problem and would like to be contacted by a lawyer at no cost or obligation, please fill in our form on the right.

Reader Comments

Posted by

on
I was on the medicine for almost 10 yrs, I suffered migraines that were so bad and I never new where they came from

Posted by

on
I was prescribed Topamx for psychiatric related reasons for quite a while, when I was taken off the medication Topamax I suffered from a headache so intense I couldn't sleep for almost48 hours!!

Add Your Comment on This Issue

Please read our comment guidelines before posting.


Note: Your name will be published with your comment.


Your email will only be used if a response is needed.

Request Legal Help